JP2020519669A - ホモタウリンおよびその塩の製剤 - Google Patents

ホモタウリンおよびその塩の製剤 Download PDF

Info

Publication number
JP2020519669A
JP2020519669A JP2019563191A JP2019563191A JP2020519669A JP 2020519669 A JP2020519669 A JP 2020519669A JP 2019563191 A JP2019563191 A JP 2019563191A JP 2019563191 A JP2019563191 A JP 2019563191A JP 2020519669 A JP2020519669 A JP 2020519669A
Authority
JP
Japan
Prior art keywords
pellet
hpmc
less
release
ethyl cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019563191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519669A5 (cg-RX-API-DMAC7.html
Inventor
ジョーンズ,スティーブン
ペイエ,ケネス
ドニパーシ,バドリーナート
Original Assignee
コンフルーエンス ファーマシューティカルズ,エルエルシー
コンフルーエンス ファーマシューティカルズ,エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンフルーエンス ファーマシューティカルズ,エルエルシー, コンフルーエンス ファーマシューティカルズ,エルエルシー filed Critical コンフルーエンス ファーマシューティカルズ,エルエルシー
Publication of JP2020519669A publication Critical patent/JP2020519669A/ja
Publication of JP2020519669A5 publication Critical patent/JP2020519669A5/ja
Priority to JP2023073242A priority Critical patent/JP7499539B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019563191A 2017-05-17 2018-05-17 ホモタウリンおよびその塩の製剤 Pending JP2020519669A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023073242A JP7499539B2 (ja) 2017-05-17 2023-04-27 ホモタウリンおよびその塩の製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762507532P 2017-05-17 2017-05-17
US62/507,532 2017-05-17
US201862660690P 2018-04-20 2018-04-20
US62/660,690 2018-04-20
PCT/US2018/033205 WO2018213589A1 (en) 2017-05-17 2018-05-17 Formulations of homotaurines and salts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023073242A Division JP7499539B2 (ja) 2017-05-17 2023-04-27 ホモタウリンおよびその塩の製剤

Publications (2)

Publication Number Publication Date
JP2020519669A true JP2020519669A (ja) 2020-07-02
JP2020519669A5 JP2020519669A5 (cg-RX-API-DMAC7.html) 2021-07-26

Family

ID=64274653

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019563191A Pending JP2020519669A (ja) 2017-05-17 2018-05-17 ホモタウリンおよびその塩の製剤
JP2023073242A Active JP7499539B2 (ja) 2017-05-17 2023-04-27 ホモタウリンおよびその塩の製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023073242A Active JP7499539B2 (ja) 2017-05-17 2023-04-27 ホモタウリンおよびその塩の製剤

Country Status (8)

Country Link
US (1) US12042566B2 (cg-RX-API-DMAC7.html)
EP (1) EP3624788A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020519669A (cg-RX-API-DMAC7.html)
KR (1) KR20200005576A (cg-RX-API-DMAC7.html)
AU (2) AU2018269557B2 (cg-RX-API-DMAC7.html)
IL (1) IL270654B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018213589A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201908264B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3624788A4 (en) 2017-05-17 2021-03-03 Confluence Pharmaceuticals, LLC FORMULATIONS OF HOMOTAURIN AND SALT THEREOF
WO2025163673A1 (en) * 2024-01-29 2025-08-07 Micro Labs Limited Dose-dumping resistant tablets of acamprosate calcium

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04224517A (ja) * 1990-04-17 1992-08-13 Giuliani Spa 標的制御釈放薬剤
JP2001199878A (ja) * 1999-09-13 2001-07-24 Lab Del Dr Esteve Sa 酸に不安定ベンズイミダゾールを含有する修飾された放出特性の経口用固形製剤
JP2012254993A (ja) * 2004-05-11 2012-12-27 Bayer Pharma AG バルデナフィルを含有する制御放出製剤
JP2014508812A (ja) * 2011-03-23 2014-04-10 アイアンショア ファーマシューティカルズ アンド ディベロップメント, インコーポレイテッド 注意欠陥障害の処置のための方法および組成物
JP2015131864A (ja) * 1998-10-01 2015-07-23 エラン ファーマ インターナショナル,リミティド 徐放性ナノ粒子組成物
JP2015528504A (ja) * 2012-09-12 2015-09-28 モノソル アールエックス リミテッド ライアビリティ カンパニー 抗疼痛及び抗嘔気及び/又は抗嘔吐組み合わせ組成物
WO2016179252A1 (en) * 2015-05-04 2016-11-10 Confluence Pharmaceuticals, Llc Sprinkle formulations of acamprosate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01280192A (ja) 1988-10-25 1989-11-10 Nichibei Co Ltd ブラインド内装サッシ
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
FR2775188B1 (fr) 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
AU765603C (en) 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
RU2375048C2 (ru) 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
CA2504471A1 (en) * 2004-06-18 2005-12-18 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
DE102007009243A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
WO2009004082A2 (en) 2007-07-05 2009-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticonvulsive pharmaceutical compositions
ES2530047T3 (es) 2009-02-12 2015-02-26 Indiana University Research And Technology Corporation Material y métodos para el tratamiento de trastornos del desarrollo que incluyen autismo idiopático y comórbido
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9195775B2 (en) 2009-06-26 2015-11-24 Iii Holdings 2, Llc System and method for managing and/or rendering internet multimedia content in a network
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US9000046B2 (en) * 2010-09-28 2015-04-07 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
RS53227B (sr) * 2011-03-01 2014-08-29 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
WO2013002584A2 (ko) 2011-06-28 2013-01-03 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
AU2012345659B2 (en) * 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
RU2675252C2 (ru) 2012-07-22 2018-12-18 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн МОДУЛЯЦИЯ УРОВНЕЙ sAPP, sAPPα И BDNF У ИНДИВИДУУМОВ С ДИАГНОЗОМ FXS И ASD
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3104850A1 (en) * 2014-02-11 2016-12-21 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
AU2016303610A1 (en) 2015-08-04 2018-02-01 Confluence Pharmaceuticals, Llc Combination therapy using acamprosate and D-cycloserine
JP6066009B1 (ja) 2016-06-16 2017-01-25 富士電機株式会社 ガス絶縁開閉装置用操作器及びそれを用いたガス絶縁開閉装置
EP3624788A4 (en) 2017-05-17 2021-03-03 Confluence Pharmaceuticals, LLC FORMULATIONS OF HOMOTAURIN AND SALT THEREOF

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04224517A (ja) * 1990-04-17 1992-08-13 Giuliani Spa 標的制御釈放薬剤
JP2015131864A (ja) * 1998-10-01 2015-07-23 エラン ファーマ インターナショナル,リミティド 徐放性ナノ粒子組成物
JP2001199878A (ja) * 1999-09-13 2001-07-24 Lab Del Dr Esteve Sa 酸に不安定ベンズイミダゾールを含有する修飾された放出特性の経口用固形製剤
JP2012254993A (ja) * 2004-05-11 2012-12-27 Bayer Pharma AG バルデナフィルを含有する制御放出製剤
JP2014508812A (ja) * 2011-03-23 2014-04-10 アイアンショア ファーマシューティカルズ アンド ディベロップメント, インコーポレイテッド 注意欠陥障害の処置のための方法および組成物
JP2015528504A (ja) * 2012-09-12 2015-09-28 モノソル アールエックス リミテッド ライアビリティ カンパニー 抗疼痛及び抗嘔気及び/又は抗嘔吐組み合わせ組成物
WO2016179252A1 (en) * 2015-05-04 2016-11-10 Confluence Pharmaceuticals, Llc Sprinkle formulations of acamprosate

Also Published As

Publication number Publication date
CA3062834A1 (en) 2018-11-22
IL270654B2 (en) 2024-07-01
WO2018213589A1 (en) 2018-11-22
AU2021225172B2 (en) 2023-04-06
JP7499539B2 (ja) 2024-06-14
AU2018269557A1 (en) 2019-11-28
AU2018269557B2 (en) 2021-06-03
EP3624788A4 (en) 2021-03-03
ZA201908264B (en) 2022-03-30
US12042566B2 (en) 2024-07-23
US20200163895A1 (en) 2020-05-28
AU2021225172A1 (en) 2021-09-30
IL270654A (en) 2020-01-30
IL270654B1 (en) 2024-03-01
EP3624788A1 (en) 2020-03-25
KR20200005576A (ko) 2020-01-15
JP2023099100A (ja) 2023-07-11

Similar Documents

Publication Publication Date Title
RU2428176C2 (ru) Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
AU2005307052B2 (en) Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane
JP6480420B2 (ja) コルヒチンの徐放性製剤およびその使用方法
US20160015642A1 (en) Controlled dose drug delivery system
US20100047343A1 (en) Multiparticulate formulation having tramadol in immediate and controlled release form
CN106390129A (zh) 含有高剂量和低剂量药物的组合的口腔崩解片组合物
CN112789042A (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
JP7026347B2 (ja) アカンプロサートのスプリンクル製剤
US8927010B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
US9034902B2 (en) Methods for treatment of attention deficit hyperactivity disorder
JP7499539B2 (ja) ホモタウリンおよびその塩の製剤
CA3200952A1 (en) Sustained release solid dosage forms for modulating the colonic microbiome
CN115667235A (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
US12472149B2 (en) Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
EP3331502B1 (en) Controlled release propiverine formulations
CA3062834C (en) Formulations of homotaurines and salts thereof
RU2325905C2 (ru) Содержащее 3-(3-диметиламино-1-этил-2-метилпропил)фенол лекарственное средство с замедленным высвобождением действующего вещества
RU2744270C2 (ru) Прессованный фармацевтический препарат
HK40044922A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220822

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221227